Wealth Enhancement Advisory Services
VKTX icon

Wealth Enhancement Advisory Services’s Viking Therapeutics VKTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$5.91K – 3119
2024
Q3 		$5.91K Buy
+500
New +$29.3K ﹤0.01% 2743

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

Wealth Enhancement Advisory Services's VKTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Viking Therapeutics (VKTX) stake by 22% in Q2 2026, buying an estimated $73.4K and bringing the position to 12,691 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #2701.

Wealth Enhancement Advisory Services first reported a position in VKTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.63M in Q3 2024. 195 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 12,691 shares of Viking Therapeutics worth $493K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 2,271 Viking Therapeutics shares in Q2 2026, an estimated $73.4K.
  • Viking Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2701 holding.
  • Wealth Enhancement Advisory Services first reported a position in Viking Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Wealth Enhancement Advisory Services's Viking Therapeutics position peaked at $1.63M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.